Risankizumab Shows Lower Drug Change Rate in Psoriatic Arthritis
Final 37-month VALUE study results compare drug change rates across biologic treatments for patients with psoriasis and psoriatic arthritis.
Updated on Nov. 2, 2026 in Arthritis
Final results from the VALUE study, presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, Nevada, found that 18.2% of risankizumab recipients had a drug change by month 37 versus 33.1% of patients on other biologics. The difference was statistically significant (P < .01).
Why it matters
Drug changes often reflect treatment failure, side effects or loss of response, so a lower change rate suggests more durable disease control for patients with psoriatic arthritis. The findings may inform how clinicians weigh biologic options over the long term.
The analysis compared 121 patients per group, matched from 462 psoriatic arthritis patients in a prospective observational study, with drug change rates of 18.2% for risankizumab and 33.1% for other biologics by month 37. The study is observational and did not test whether the difference reflects a true treatment effect.
The players
VALUE study
A multicountry, prospective, observational study (NCT03982394) comparing long-term drug change rates among biologic treatments for psoriasis and psoriatic arthritis.
AbbVie
A global biopharmaceutical company that markets risankizumab and co-sponsored the VALUE study.
The details
Researchers from Monash University, the University of Toronto, the University of Lübeck and AbbVie analyzed patients with psoriatic arthritis diagnosed by a rheumatologist using 1:1 propensity score matching with exact matching on prior biologic use. Drug changes occurred in 57.1% of patients receiving a TNF inhibitor, a comparison that was significantly higher than risankizumab (P < .001).
Timeline
2025 Fall Clinical meeting: an interim analysis showed higher risankizumab drug survival at 25 months.
Month 37: final VALUE follow-up point at which drug change rates were compared.
2026 Fall Clinical Dermatology Conference: final VALUE results were presented in Las Vegas, Nevada.
Health Landscape
The final VALUE results extend the study's 2025 interim analysis, which first reported higher risankizumab drug survival at 25 months. Together the two readouts add longer-term observational evidence to the comparison of IL-23 and other biologic classes in psoriatic arthritis.
Patients with psoriatic arthritis who are weighing biologic options may find longer-term switching data useful when discussing treatment durability with their rheumatologist. The study does not establish that any one drug will work better for an individual, so decisions should rest on clinical evaluation.
The takeaway
Lower drug change rates in observational data are a useful signal of durability, but they do not replace head-to-head randomized evidence. Patients should review long-term outcomes with their clinicians before changing therapy.
Further reading
Learn more about the Arthritis treatments and research covered on Wisevoter.
Source note: This article includes information reported by Hcplive.
